![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
TP Su
A portion of the specific binding of tritiated SKF-10047 to the guinea- pig brain suspension of the particulate fraction is not inhibited by the strong narcotic analgesic l-etorphine. The binding properties of these etorphine-inaccessible (EI) sites were examined. The specific binding of [3H]SKF-10047 to the EI sites is saturable. Scatchard analysis of the saturation curve revealed a single class of binding sites with apparent Kd of 252 nM and an estimated Bmax of 663 fmol/mg of protein. The EI binding was reduced by heat treatment, trypsin digestion and phospholipase C digestion. The presence of sodium ions slightly increased specific EI binding. Lithium ion increased the EI binding by about 38% at the optimal concentration of 1 mM. Divalent cations such as Mg++, Ca++ and Mn++ reduced EI binding. Morphine-like drugs such as morphine, levorphanol and naltrexone were poor inhibitors for the EI binding, whereas opioid derivatives such as pentazocine, dextrallorphan, cyclazocine, SKF-10047 and dextrorphan were potent inhibitors. Nonopioid drugs such as haloperidol, imipramine, pimozide and propranolol were also potent inhibitors of the EI binding. Distribution of the EI sites in brain was different from that of the mu receptor: highest concentration of EI sites was found in brainstem, midbrain and cerebellum, whereas lower concentrations were found in striatum and cortex. It is suggested that EI sites are not mu receptors but may represent sigma receptors in the central nervous system, mediating psychotomimetic effects of several opioids and other drugs.
This article has been cited by other articles:
|
|
 |
|
  A. Pal, U. B. Chu, S. Ramachandran, D. Grawoig, L.-W. Guo, A. R. Hajipour, and A. E. Ruoho Juxtaposition of the Steroid Binding Domain-like I and II Regions Constitutes a Ligand Binding Site in the {sigma}-1 Receptor J. Biol. Chem., July 11, 2008; 283(28): 19646 - 19656. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Pal, A. R. Hajipour, D. Fontanilla, S. Ramachandran, U. B. Chu, T. Mavlyutov, and A. E. Ruoho Identification of Regions of the {sigma}-1 Receptor Ligand Binding Site Using a Novel Photoprobe Mol. Pharmacol., October 1, 2007; 72(4): 921 - 933. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Gray and B. L. Roth Molecular Targets for Treating Cognitive Dysfunction in Schizophrenia Schizophr Bull, September 1, 2007; 33(5): 1100 - 1119. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Jiang, B. Mysona, Y. Dun, J. P. Gnana-Prakasam, N. Pabla, W. Li, Z. Dong, V. Ganapathy, and S. B. Smith Expression, Subcellular Localization, and Regulation of Sigma Receptor in Retinal Muller Cells Invest. Ophthalmol. Vis. Sci., December 1, 2006; 47(12): 5576 - 5582. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Yagasaki, T. Numakawa, E. Kumamaru, T. Hayashi, T.-P. Su, and H. Kunugi Chronic Antidepressants Potentiate via Sigma-1 Receptors the Brain-derived Neurotrophic Factor-induced Signaling for Glutamate Release J. Biol. Chem., May 5, 2006; 281(18): 12941 - 12949. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Zhang and J. Cuevas {sigma} Receptor Activation Blocks Potassium Channels and Depresses Neuroexcitability in Rat Intracardiac Neurons J. Pharmacol. Exp. Ther., June 1, 2005; 313(3): 1387 - 1396. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Hayashi and T.-P. Su {sigma}-1 Receptors ({sigma}1 Binding Sites) Form Raft-Like Microdomains and Target Lipid Droplets on the Endoplasmic Reticulum: Roles in Endoplasmic Reticulum Lipid Compartmentalization and Export J. Pharmacol. Exp. Ther., August 1, 2003; 306(2): 718 - 725. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Hayashi and T.-P. Su Intracellular Dynamics of {sigma}-1 Receptors ({sigma}1 Binding Sites) in NG108-15 Cells J. Pharmacol. Exp. Ther., August 1, 2003; 306(2): 726 - 733. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Takebayashi, T. Hayashi, and T.-P. Su Nerve Growth Factor-Induced Neurite Sprouting in PC12 Cells Involves sigma -1 Receptors: Implications for Antidepressants J. Pharmacol. Exp. Ther., December 1, 2002; 303(3): 1227 - 1237. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Vanecek, W. D. Essman, D. P. Taylor, and J. H. Woods Discriminative Stimulus Characteristics of BMY 14802 in the Pigeon J. Pharmacol. Exp. Ther., January 1, 1998; 284(1): 1 - 9. [Abstract] [Full Text]
|
|
|
|
|
|
O. Jbilo, H. Vidal, R. Paul, N. De Nys, M. Bensaid, S. Silve, P. Carayon, D. Davi, S. Galiegue, B. Bourrie, et al. Purification and Characterization of the Human SR 31747A-binding Protein. A NUCLEAR MEMBRANE PROTEIN RELATED TO YEAST STEROL ISOMERASE J. Biol. Chem., October 24, 1997; 272(43): 27107 - 27115. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. R. Whittemore, V. I. Ilyin, and R. M. Woodward Antagonism of N-Methyl-D-Aspartate Receptors by sigma Site Ligands: Potency, Subtype-Selectivity and Mechanisms of Inhibition J. Pharmacol. Exp. Ther., July 1, 1997; 282(1): 326 - 338. [Abstract] [Full Text]
|
|
|
|
 |
|
 B.E. Leonard and C.D. Nicholson Sigma ligands as potential psychotropic drugs J Psychopharmacol, January 1, 1994; 8(1): 64 - 65. [PDF]
|
|
|
|
 |
|
 T. Su, E. London, and J. Jaffe Steroid binding at sigma receptors suggests a link between endocrine, nervous, and immune systems Science, April 8, 1988; 240(4849): 219 - 221. [Abstract] [PDF]
|
|
|
|
|
|
S. Snyder Drug and neurotransmitter receptors in the brain Science, April 6, 1984; 224(4644): 22 - 31. [Abstract] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
